Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comirnaty XBB.1.5 vaccination for prevention of type 1 diabetes autoimmunity in genetically high-risk infants
ISRCTN82491599Phase 4Recruiting
- Sponsor
- Klinikum rechts der Isar
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 4, randomised, double-blind trial of tozinameran in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Klinikum rechts der Isar. Primary endpoint: Time to persistent confirmed islet autoantibodies or type 1 diabetes. Started Oct 2024; status: recruiting.
02
Drugs
tozinameran
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ISRCTN82491599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN82491599.